These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 14529363)
1. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Lad SP; Neet KE; Mufson EJ Curr Drug Targets CNS Neurol Disord; 2003 Oct; 2(5):315-34. PubMed ID: 14529363 [TBL] [Abstract][Full Text] [Related]
2. The cholinergic system, nerve growth factor and the cytoskeleton. Niewiadomska G; Mietelska-Porowska A; Mazurkiewicz M Behav Brain Res; 2011 Aug; 221(2):515-26. PubMed ID: 20170684 [TBL] [Abstract][Full Text] [Related]
3. APP, NGF & the 'Sunday-driver' in a Trolley on the Road. Heese K; Inoue N; Nagai Y; Sawada T Restor Neurol Neurosci; 2004; 22(2):131-6. PubMed ID: 15272147 [TBL] [Abstract][Full Text] [Related]
4. Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease. Counts SE; Che S; Ginsberg SD; Mufson EJ J Chem Neuroanat; 2011 Oct; 42(2):111-7. PubMed ID: 21397006 [TBL] [Abstract][Full Text] [Related]
5. Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Capsoni S; Tiveron C; Vignone D; Amato G; Cattaneo A Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12299-304. PubMed ID: 20566851 [TBL] [Abstract][Full Text] [Related]
6. Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Tiernan CT; Ginsberg SD; He B; Ward SM; Guillozet-Bongaarts AL; Kanaan NM; Mufson EJ; Counts SE Neurobiol Dis; 2018 Sep; 117():125-136. PubMed ID: 29859871 [TBL] [Abstract][Full Text] [Related]
7. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. Mufson EJ; Ma SY; Dills J; Cochran EJ; Leurgans S; Wuu J; Bennett DA; Jaffar S; Gilmor ML; Levey AI; Kordower JH J Comp Neurol; 2002 Feb; 443(2):136-53. PubMed ID: 11793352 [TBL] [Abstract][Full Text] [Related]
8. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model. Capsoni S; Brandi R; Arisi I; D'Onofrio M; Cattaneo A CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):635-47. PubMed ID: 21631402 [TBL] [Abstract][Full Text] [Related]
9. The cholinergic system in aging and neuronal degeneration. Schliebs R; Arendt T Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918 [TBL] [Abstract][Full Text] [Related]
10. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Mufson EJ; Counts SE; Perez SE; Ginsberg SD Expert Rev Neurother; 2008 Nov; 8(11):1703-18. PubMed ID: 18986241 [TBL] [Abstract][Full Text] [Related]
11. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. Ginsberg SD; Che S; Wuu J; Counts SE; Mufson EJ J Neurochem; 2006 Apr; 97(2):475-87. PubMed ID: 16539663 [TBL] [Abstract][Full Text] [Related]
13. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. Ubhi K; Rockenstein E; Vazquez-Roque R; Mante M; Inglis C; Patrick C; Adame A; Fahnestock M; Doppler E; Novak P; Moessler H; Masliah E J Neurosci Res; 2013 Feb; 91(2):167-77. PubMed ID: 23152192 [TBL] [Abstract][Full Text] [Related]
14. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Cuello AC; Bruno MA; Bell KF Curr Alzheimer Res; 2007 Sep; 4(4):351-8. PubMed ID: 17908036 [TBL] [Abstract][Full Text] [Related]
15. Focused ultrasound delivery of a selective TrkA agonist rescues cholinergic function in a mouse model of Alzheimer's disease. Xhima K; Markham-Coultes K; Nedev H; Heinen S; Saragovi HU; Hynynen K; Aubert I Sci Adv; 2020 Jan; 6(4):eaax6646. PubMed ID: 32010781 [TBL] [Abstract][Full Text] [Related]
16. Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. Xhima K; Markham-Coultes K; Hahn Kofoed R; Saragovi HU; Hynynen K; Aubert I Brain; 2022 Aug; 145(8):2806-2822. PubMed ID: 34919633 [TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402 [TBL] [Abstract][Full Text] [Related]
18. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Counts SE; Nadeem M; Wuu J; Ginsberg SD; Saragovi HU; Mufson EJ Ann Neurol; 2004 Oct; 56(4):520-31. PubMed ID: 15455399 [TBL] [Abstract][Full Text] [Related]
19. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. Counts SE; Mufson EJ J Neuropathol Exp Neurol; 2005 Apr; 64(4):263-72. PubMed ID: 15835262 [TBL] [Abstract][Full Text] [Related]
20. NGF and the Amyloid Precursor Protein in Alzheimer's Disease: From Molecular Players to Neuronal Circuits. Triaca V; Ruberti F; Canu N Adv Exp Med Biol; 2021; 1331():145-165. PubMed ID: 34453297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]